chinese glp-1 Innovent's weight-loss drug highlights China challenge for Novo, Lilly China's Innovent says its GLP-1
Description
Hims & Hers Health (NYSE:HIMS) is facing a patent infringement lawsuit from Novo Nordisk over its compounded weight loss drugs
VANCOUVER, WA / ACCESS Newswire / July 16, 2026 / LIR Life Sciences Corp
others seek natural alternatives to the prescriptions
SAN FRANCISCO Hims & Hers Health, Inc
Semaglutide showed indirect behavioral benefits in real-world observational data
Upcoming Removal of Selected GLP-1 Drugs from Medi-Cal Rx Effective January 1, 2026, Californias Medi-Cal Rx program will remove certain medications from its contract drug list
